38 results about "Urination disorder" patented technology

The purpose of the present invention is to provide a medicinal agent which is useful for amelioration or treatment of chronic prostatitis, interstitial cystitis and / or urination disorders. The present invention relates to a novel medical use of an extract from inflamed tissues inoculated with vaccinia virus, and more particularly, it relates to an ameliorating or therapeutic agent for chronic prostatitis, interstitial cystitis and / or urination disorders containing the extract as an active ingredient. The medicinal agent of the present invention containing the extract as an active ingredient is extremely useful as a highly effective and highly safe ameliorating or therapeutic agent for chronic prostatitis, interstitial cystitis and / or urination disorders.

Provided can be used as MC 4 Agonist compounds. MC 4 Receptor agonists were studied and it was confirmed that piperazine derivatives have MC 4 receptor agonist action, thus completing the present invention. The piperazine derivatives of the present invention have MC 4 Receptor agonist action, can act as bladder, urological disorders, especially hypoactive bladder, hypotonic bladder, non-contracting bladder, detrusor hypoactivity, neurogenic bladder, urethral insufficiency, detrusor-extraurethral Prophylactic or therapeutic agent use for sphincter dyssynergia and voiding disorder in prostatic hypertrophy.

The present invention provides the ability to be used as MC 4 Compounds used as agonists. MC 4 Research on receptor agonists was carried out, and the effect of piperazine derivatives was confirmed, thereby completing the present invention. That is, the piperazine derivatives of the present invention have MC 4 Receptor agonist action, can be used as bladder and urinary tract diseases, especially hypoactive bladder, hypotonic bladder, non-contracting bladder, detrusor hypoactivity, neurogenic bladder, urethral insufficiency, detrusor extraurethral Prophylactic and / or therapeutic agent use for sphincter dyssynergia and voiding disorders in benign prostatic hypertrophy.

The invention discloses a new Chinese medicinal composition for treating medial headache and migraine and a preparation method thereof. The Chinese medicinal composition comprises the following raw material medicaments: szechuan lovage rhizome, root of red-rooted salvia, costustoot, fenugreek lysimachia, benzoin, tangerine peel, radix curcumae, cyperus rotunus, golden thread, baical skullcap root, cassia twig, incised notopterygium rhizome, angelica dahurlica, kudzuvine root, peach seed, safflower, common burreed rhizome, zedoary, pangolin scales, raw astragalus, radix paeoniae alba, red paeony root, tall gastrodia tuber, gambir plant, storax, grassleaf sweelflag rhizome, fineleaf schizonepeta herb, divaricate saposhnikovia root, radix ephedrae, weeping forsythia, manchurian wildginger, biond magnolia flower, mentha haplocalyx, raw rehmannia root, szechwan chinaberry fruit, rose, radix pseudo-ginseng, rosewood heart wood, garden burnet root, leonurus heterophyllus, cowherb seed, ground beeltle, sappan wood, dragon's blood, pinellia tuber and the like. The Chinese medicinal composition can be prepared into any oral administration preparation used commonly according to the conventional method of Chinese medicinal preparations. The Chinese medicinal composition can improve headaches of bitamporal, foreheads and orbital parts, pulsatile headache or boring pain and the like, and associated symptoms of nausea, vomiting, blurred vision, frequent micturition, urination disorder, stuffy nose, palpitation, hypertension, hypotension, arrhythmia, megrim, ataxia, diplopia, hearing loss, tinnitus, disturbance of consciousness and the like obviously, and has definite clinical effects, obvious curative effect and quick response. The Chinese medicinal composition of the invention is combined by adopting medicinal and edible medicaments formulated by National Formulary basically, and thus, the Chinese medicinal composition has the advantages of low cost and no toxic or side effect.

The invention provides a bladder function recovery apparatus. The bladder function recovery apparatus comprises an irrigation device, a urine drainage device, a bladder pressure acquisition unit and a central processing unit. The irrigation device comprises an irrigation bag, an irrigation tube and a first control component and is used for charging liquid medium in the irrigation bag to a bladder. The urine drainage device comprises a drainage bag, a urine drainage tube and a second control component and is used for draining the liquid medium in the bladder into the drainage bag. The bladder pressure acquisition unit is communicated with the urine drainage device. The central processing unit is connected with the first control component, the second control component and the bladder pressure acquisition unit and compares bladder pressure with maximal preset pressure and minimal preset pressure. When the bladder pressure is equal to or larger than the preset pressure, the first control component is closed, and the second control component is opened. When the bladder pressure is smaller than or equal to the minimal preset pressure, the second control component is closed, and the first control component is opened. The bladder function recovery apparatus can be used for bladder function recovery training for a patient with an indwelling catheter, and cystatrophy caused by long-term urination disorder is prevented.

[Problem] To provide a compound that can be used as an active ingredient of a pharmaceutical composition for treating urinary storage disorders, voiding disorders, and lower urinary tract diseases. [Solution] The inventors have found that 2-aminothiazole derivatives have excellent muscarinic M 3 receptor positive allosteric modulator activity, and is expected to act as a 3 A prophylactic or therapeutic agent for bladder / urological diseases related to receptor-mediated bladder contraction, thereby completing the present invention. The 2-aminothiazole derivatives or salts thereof of the present invention are expected to act as 3 A prophylactic or therapeutic agent for bladder / urological diseases related to receptor-mediated bladder contraction (such as voiding disorders such as hypoactive bladder).